Across TCGA pan-cancer cohorts, ANGPTL5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANGPTL5 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANGPTL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANGPTL5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and LUSC are the cancer types where ANGPTL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.595	0.913	<.001	25	view →
UCEC	DFS	Median	All	1.000	0.626	.012	18	view →
LUSC	OS	Median	II,III,IV	0.236	0.633	.013	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANGPTL5 tumor-vs-normal RNA expression · all ANGPTL5 data types